Mod Rheumatol. 2006;16(4):251-5.

Development of interstitial pneumonia in a rheumatoid arthritis patient treated with infliximab, an anti-tumor necrosis factor alpha-neutralizing antibody.

Mori S, Imamura F, Kiyofuji C, Sugimoto M.

Source

Division of Rheumatology, Department of Medicine, National Hospital Organization, Kumamoto Saishunso National Hospital, 2659 Suya Kohshi, Kumamoto, 861-1196, Japan. moris@saisyunsou.hosp.go.jp

Abstract

Infliximab, an anti-tumor necrosis factor (TNF)-alpha antibody, was introduced to a 66-year-old woman with methotrexate (MTX)-resistant rheumatoid arthritis (RA). Although the TNF-blocking therapy was successful, she developed noninfectious interstitial pneumonia (IP) after a second infusion of infliximab. In most cases reported previously, infliximab-associated noninfectious IP occurred after a second or third infusion of infliximab, and this type of IP was more fatal in comparison with cases associated with MTX treatment alone. Keeping a sharp lookout on IP development during this period is crucial to the success of infliximab treatment. After MTX discontinuation and steroid pulse therapy, our patient made a dramatic recovery from IP.

PMID:: 16906378; [PubMed - indexed for MEDLINE]

LinkOut - more resources

Full Text Sources

Other Literature Sources

Labome Researcher Resource - ExactAntigen/Labome

Medical

Supplemental Content

Save items

Related citations in PubMed

Pulmonary complications of infliximab therapy in patients with rheumatoid arthritis. [J Rheumatol. 2006]
Pulmonary complications of infliximab therapy in patients with rheumatoid arthritis.
Ostör AJ, Chilvers ER, Somerville MF, Lim AY, Lane SE, Crisp AJ, Scott DG. J Rheumatol. 2006 Mar; 33(3):622-8.
Review Invasive pulmonary aspergillosis soon after therapy with infliximab, a tumor necrosis factor-alpha-neutralizing antibody: a possible healthcare-associated case? [Infect Control Hosp Epidemiol....]
Review Invasive pulmonary aspergillosis soon after therapy with infliximab, a tumor necrosis factor-alpha-neutralizing antibody: a possible healthcare-associated case?
De Rosa FG, Shaz D, Campagna AC, Dellaripa PE, Khettry U, Craven DE. Infect Control Hosp Epidemiol. 2003 Jul; 24(7):477-82.
Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. [Arthritis Rheum. 2009]
Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis.
Du Pan SM, Dehler S, Ciurea A, Ziswiler HR, Gabay C, Finckh A, Swiss Clinical Quality Management Physicians. Arthritis Rheum. 2009 May 15; 61(5):560-8.
Interstitial pneumonitis associated with infliximab therapy without methotrexate treatment. [Rheumatol Int. 2009]
Interstitial pneumonitis associated with infliximab therapy without methotrexate treatment.
Taki H, Kawagishi Y, Shinoda K, Hounoki H, Ogawa R, Sugiyama E, Tobe K. Rheumatol Int. 2009 Dec; 30(2):275-6.
Review A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. [Health Technol Assess. 2006]
Review A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, Fry-Smith A, Burls A. Health Technol Assess. 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229.

See reviews... See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in Books
NCBI Bookshelf books that cite the current articles.

Recent activity

Clear Turn Off Turn On

Development of interstitial pneumonia in a rheumatoid arthritis patient treated ...
Development of interstitial pneumonia in a rheumatoid arthritis patient treated with infliximab, an anti-tumor necrosis factor alpha-neutralizing antibody.
Mod Rheumatol. 2006 ;16(4):251-5.

PubMed
The mouse W/c-kit locus.
The mouse W/c-kit locus.
Ciba Found Symp. 1990 ;148:158-66; discussion 166-72.

PubMed
Allelic dilution obscures detection of a biologically significant resistance mut...
Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.
J Clin Invest. 2006 Oct ;116(10):2695-706. Epub 2006 Aug 10 .

PubMed
PARP-1 inhibitors: are they the long-sought genetically specific drugs for BRCA1...
PARP-1 inhibitors: are they the long-sought genetically specific drugs for BRCA1/2-associated breast cancers?
Int J Med Sci. 2006 Jul 15 ;3(4):117-23.

PubMed
The management of the atlanto-occipital and atlanto-axial joint pain.
The management of the atlanto-occipital and atlanto-axial joint pain.
Pain Physician. 2000 Jul ;3(3):289-93.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to:

Development of interstitial pneumonia in a rheumatoid arthritis patient treated with infliximab, an anti-tumor necrosis factor alpha-neutralizing antibody.

Source

Abstract

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Supplemental Content

Save items

Related citations in PubMed

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information